Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study

European Heart Journal

Volumn 32, Issue 17, 2011, Pages 2135-2142

  Verma, Subodh ^a,b   Gupta, Milan ^a,b,c   Holmes, Daniel T ^d   Xu, Liqin ^e   Teoh, Hwee ^a,b   Gupta, Sunayna ^a   Yusuf, Salim ^c,e   Lonn, Eva M ^c,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Canadian Cardiovascular Research Network   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Cardiovascular diseases; Direct renin inhibitors; Mortality; Renin; Reninangiotensin system; Risk factors

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIURETIC AGENT; RAMIPRIL; RENIN;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PLASMA RENIN ACTIVITY; PREDICTIVE VALUE; PREVENTION STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; BIOLOGICAL MARKERS; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PROGNOSIS; PROSPECTIVE STUDIES; RENIN; STROKE;

EID: 79957832677     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr066     Document Type: Article

References (33)

1. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766. (Pubitemid 37093915)
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
3. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensinconverting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-588. (Pubitemid 44209181)
4. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327: 669-677.
5. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906. (Pubitemid 37409706)
6. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
7. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559. (Pubitemid 351522739)
8. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208-1219. (Pubitemid 46527856)
9. Laragh JH. The renin system and future trends in management of high blood pressure. Clin Exp Hypertens 1980;2:525-552. (Pubitemid 11230189)
10. Laragh JH, Sealey JE. Abnormal sodium metabolism and plasma renin activity (renal renin secretion) and the vasoconstriction volume hypothesis: implications for pathogenesis and treatment of hypertension and its vascular consequences (heart attack, stroke). Clin Chem 1991;37:1820-1827. (Pubitemid 121000618)
11. Brunner HR, Gavras H, Laragh JH. Specific inhibition of the renin-angiotensin system: a key to understanding blood pressure regulation. Prog Cardiovasc Dis 1974;17:87-98.
12. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441-449.
13. Brunner HR, Sealey JE, Laragh JH. Renin as a risk factor in essential hypertension: more evidence. Am J Med 1973;55:295-302.
14. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823. (Pubitemid 14035089)
15. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI40-VI48. (Pubitemid 23164221)
16. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, Cohn JN. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25:292-299. (Pubitemid 38295437)
17. Rouleau JL, Packer M, Moyé L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy TE, Lamas G, Gottlieb SS, McCans J, Nadeau C, Delage F, Wun C-C C, Pfeffer MA. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994;24:583-591. (Pubitemid 24295729)
18. Tsutamoto T, Sakai H, Tanaka T, Fujii M, Yamamoto T, Wada A, Ohnishi M, Horie M. Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure. Circ J 2007;71:915-921. (Pubitemid 46833931)
19. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-1104.
20. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997;10:1-8. (Pubitemid 27038966)
21. Aronow WS, Ahn C, Kronzon I, Gutstein H. Association of plasma renin activity and echocardiographic left ventricular hypertrophy with frequency of new coronary events and new atherothrombotic brain infarction in older persons with systemic hypertension. Am J Cardiol 1997;79:1543-1545. (Pubitemid 27251082)
22. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation 2005;112:110-116. (Pubitemid 40962576)
23. Doyle AE, Jerums G, Johnston CI, Louis WJ. Plasma renin levels and vascular complications in hypertension. Br Med J 1973;2:206-207.
24. Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med 1993;329:616-619. (Pubitemid 23244813)
25. Parikh NI, Gona P, Larson MG, Wang TJ, Newton-Cheh C, Levy D, Benjamin EJ, Kannel WB, Vasan RS. Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 2007;28:2644-2652. (Pubitemid 350071528)
26. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-2639. (Pubitemid 44969122)
27. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, Rupprecht HJ, Bickel C, Tiret L, Cambien F, Gerstein H, Munzel T, Yusuf S. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006;114:201-208. (Pubitemid 44297113)
28. Yusuf S, Pogue J. ACE inhibition in stable coronary artery disease. N Engl J Med 2005;352:937-939; author reply 937-939. (Pubitemid 40300307)
29. Campbell DJ. Critical review of prorenin and (pro)renin receptor research. Hypertension 2008;51:1259-1264. (Pubitemid 351555933)
30. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-1427. (Pubitemid 34596167)
31. McMurray JJV, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.
32. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358: 2433-2446. (Pubitemid 351793017)
33. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlof B. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119:530-537.